Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24,863 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.
Svarovskaia ES, Dvory-Sobol H, Parkin N, Hebner C, Gontcharova V, Martin R, Ouyang W, Han B, Xu S, Ku K, Chiu S, Gane E, Jacobson IM, Nelson DR, Lawitz E, Wyles DL, Bekele N, Brainard D, Symonds WT, McHutchison JG, Miller MD, Mo H. Svarovskaia ES, et al. Among authors: xu s. Clin Infect Dis. 2014 Dec 15;59(12):1666-74. doi: 10.1093/cid/ciu697. Epub 2014 Sep 28. Clin Infect Dis. 2014. PMID: 25266287 Free PMC article. Clinical Trial.
Development of robust hepatitis C virus genotype 4 subgenomic replicons.
Peng B, Yu M, Xu S, Lee YJ, Tian Y, Yang H, Chan K, Mo H, McHutchison J, Delaney W 4th, Cheng G. Peng B, et al. Among authors: xu s. Gastroenterology. 2013 Jan;144(1):59-61.e6. doi: 10.1053/j.gastro.2012.09.033. Epub 2012 Sep 20. Gastroenterology. 2013. PMID: 23000598
In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir.
Cheng G, Tian Y, Doehle B, Peng B, Corsa A, Lee YJ, Gong R, Yu M, Han B, Xu S, Dvory-Sobol H, Perron M, Xu Y, Mo H, Pagratis N, Link JO, Delaney W. Cheng G, et al. Among authors: xu s, xu y. Antimicrob Agents Chemother. 2016 Jan 11;60(3):1847-1853. doi: 10.1128/AAC.02524-15. Antimicrob Agents Chemother. 2016. PMID: 26824950 Free PMC article.
Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems.
Camus G, Xu S, Han B, Lu J, Dvory-Sobol H, Yu M, Cheng G, Miller MD, Doehle BP, Mo H. Camus G, et al. Among authors: xu s. Virology. 2018 Jan 15;514:134-141. doi: 10.1016/j.virol.2017.11.003. Epub 2017 Nov 22. Virology. 2018. PMID: 29175627 Free article.
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta.
Hollnberger J, Liu Y, Xu S, Chang S, Martin R, Manhas S, Aeschbacher T, Han B, Yazdi T, May L, Han D, Shornikov A, Flaherty J, Manuilov D, Suri V, Asselah T, Lampertico P, Wedemeyer H, Aleman S, Richards C, Mateo R, Maiorova E, Cihlar T, Mo H, Urban S. Hollnberger J, et al. Among authors: xu s. J Hepatol. 2023 Sep;79(3):657-665. doi: 10.1016/j.jhep.2023.04.027. Epub 2023 Apr 27. J Hepatol. 2023. PMID: 37120031 Clinical Trial.
24,863 results
You have reached the last available page of results. Please see the User Guide for more information.